# France Sacroiliitis Treatment Market > France Sacroiliitis Treatment Market Research Report By Type (Medications, Joint Injections, Joint Fusion, Radiofrequency Denervation, Electrical Stimulation) and By End-user (Hospitals, Clinics, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 18.42% - **2024:** $ 2,075.31 Million - **2025:** $ 2,457.58 Million - **2035:** $ 13,327.54 Million - **Key Players:** AbbVie Inc (US), Amgen Inc (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Novartis AG (CH), Pfizer Inc (US), Roche Holding AG (CH), Sanofi S.A. (FR) **Report ID:** MRFR/HC/52190-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/france-sacroiliitis-treatment-market-53952 --- ## Market Summary ## **France Sacroiliitis Treatment Market Overview** As per MRFR analysis, the France Sacroiliitis Treatment Market Size was estimated at 0.97 (USD Billion) in 2023. The France Sacroiliitis Treatment Market is expected to grow from 1.15 (USD Billion) in 2024 to 8.5 (USD Billion) by 2035. The France Sacroiliitis Treatment Market CAGR (growth rate) is expected to be around 19.92% during the forecast period (2025 - 2035) **Key France Sacroiliitis Treatment Market Trends Highlighted** The rising incidence of inflammatory conditions like psoriatic arthritis and ankylosing spondylitis that are associated with sacroiliitis is one of the major factors driving the sacroiliitis treatment market in France. Healthcare practitioners are placing a greater emphasis on early diagnosis and treatment choices as a result of the aging population and growing awareness of the management of chronic pain problems. The development of biologics and targeted medicines for the efficient treatment of sacroiliitis is facilitated by the French healthcare system's promotion of creative therapeutic techniques. The creation of personalized medicine based on patient profiles and accounting for genetic variables that could affect the effectiveness of treatment is one area of opportunity to be investigated in France. Better patient outcomes and adherence may result from more thorough treatment paths for sacroiliitis brought about by the increasing investment in patient-centered care and health technology assessment. Furthermore, stronger collaborations between pharmaceutical firms and academic institutions may encourage the development of innovative treatments tailored to the unique requirements of the sacroiliitis patient population. Current trends show a notable move toward integrated care models, in which rheumatologists collaborate with physiotherapists and pain management specialists to improve patients' overall treatment experiences. In addition, non-pharmacological therapies including physical therapy and lifestyle changes are becoming more popular in France as alternatives to prescription drugs.  The focus on multidisciplinary and holistic therapy is changing the way sacroiliitis is treated in France and guaranteeing that patients get all-encompassing assistance catered to their particular needs. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **France Sacroiliitis Treatment Market Drivers** **Increasing Prevalence of Chronic Inflammatory Diseases** The incidence of chronic inflammatory diseases such as ankylosing spondylitis and psoriatic arthritis is significantly increasing in France, which directly influences the France Sacroiliitis Treatment Market. According to a recent report by the French Ministry of Health, approximately 1 in 200 people in France suffer from ankylosing spondylitis, a condition tightly associated with sacroiliitis. This translates to around 330,000 patients in France alone. As the population ages and lifestyles evolve, these chronic conditions are expected to further escalate. Organizations like the French Society of Rheumatology are deeply involved in raising awareness and providing guidelines for the treatment of such conditions, ultimately fueling the growth of the treatment market in France. The growing patient population seeking treatment options is expected to stimulate demand in the France [Sacroiliitis Treatment Market](../../../reports/sacroiliitis-treatment-market-6590). **Advancements in Treatment Options** The landscape of medical treatments for sacroiliitis is evolving, with new biologics and therapeutic strategies emerging to provide better outcomes for patients. Recent developments in monoclonal antibody therapies and Janus kinase inhibitors have shown promising results in clinical trials. Research conducted by leading pharmaceutical companies, such as Sanofi and Merck, highlights that these innovative therapies can offer significant relief in symptoms for patients suffering from sacroiliitis. Additionally, the French government has been supporting research initiatives to expedite the development of new therapies through streamlined regulatory processes, directly impacting the France Sacroiliitis Treatment Market by fostering an environment conducive to advancements in treatment. **Growing Recognition of Sacroiliitis as a Serious Health Condition** Awareness campaigns and educational programs led by organizations like the European League Against Rheumatism are highlighting the significance of sacroiliitis, enabling better diagnosis and treatment among healthcare professionals and patients in France. This increased awareness is crucial, as early diagnosis can lead to more effective treatment outcomes. According to a survey conducted by the French Rheumatology Society, approximately 70% of general practitioners now understand the implications of sacroiliitis compared to just 50% five years ago. This growing recognition contributes to more patients seeking treatment and, in turn, drives the France Sacroiliitis Treatment Market towards robust growth. **France Sacroiliitis Treatment Market Segment Insights** **Sacroiliitis Treatment Market Type Insights** The France Sacroiliitis Treatment Market exhibits a robust structure segmented by Type, which includes Medications, Joint Injections, Joint Fusion, Radiofrequency Denervation, and Electrical Stimulation. This segmentation plays a critical role in addressing the diverse therapeutic needs of patients suffering from sacroiliitis, a condition characterized by inflammation of the sacroiliac joints. Medications typically represent an essential first-line approach, providing symptomatic relief and anti-inflammatory benefits, which is particularly relevant given France's evolving healthcare focus on chronic pain management. Joint Injections are increasingly popular as they offer targeted relief via corticosteroids or anesthetics, thus helping to reduce the extensive reliance on systemic therapies and presenting a minimally invasive option. The significance of Joint Fusion arises from its ability to provide long-term relief by stabilizing the affected joints, catering especially to patients with advanced sacroiliitis who may not respond to conservative treatments. Conversely, Radiofrequency Denervation, which involves using heat to disrupt nerve transmission, represents a modern advancement in minimally invasive procedures that specializes in pain management, enhancing patients' quality of life while reducing dependency on medications. Electrical Stimulation techs and devices provide another innovative treatment avenue, facilitating pain relief through neuromodulation techniques. This segment's rising acceptance underscores the mounting demand for non-pharmacological treatments, which align well with France's commitment to improving chronic pain management frameworks. As overall healthcare in France transforms, the diversification into various treatment types fuels both informed patient choices and healthcare providers' strategic planning, leading to greater overall satisfaction in managing sacroiliitis symptoms through personalized treatment approaches. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Sacroiliitis Treatment Market End-user Insights** The France Sacroiliitis Treatment Market is characterized by a diverse End-user segmentation, primarily including hospitals, clinics, and others. Hospitals play a crucial role in managing severe cases, often equipped with advanced technologies and specialized healthcare teams, making them vital for comprehensive treatment plans. Clinics, on the other hand, serve as a common point of access for patients seeking outpatient care, emphasizing convenience and immediate attention. These facilities are essential for early diagnosis and management, increasing overall patient accessibility and improving outcomes. The "others" category includes home care services and rehabilitation centers that cater to specific patient needs, enhancing the holistic approach to treatment. The increasing prevalence of sacroiliitis and growing awareness about chronic pain management are driving the demand across these End-users. Furthermore, the overall healthcare framework in France supports a collaborative care model, promoting effective patient pathways among these segments, thus further influencing the France Sacroiliitis Treatment Market dynamics. This comprehensive approach is critical in addressing the challenges faced by patients, providing them with multiple avenues for support and treatment. With ongoing advancements in treatment methodologies and patient care, the significance of each segment continues to evolve within the French healthcare landscape. **France Sacroiliitis Treatment Market Key Players and Competitive Insights** The France Sacroiliitis Treatment Market is characterized by a diverse range of treatment options aimed at addressing the pain and discomfort associated with sacroiliitis. The competitive landscape in this market is shaped by various pharmaceutical companies that have developed innovative therapeutic solutions, ranging from non-steroidal anti-inflammatory drugs to advanced biologics. These companies strive to adapt their treatments to meet the evolving needs of healthcare providers and patients, aligning with the country's healthcare regulations and patient care strategies. The market dynamics are influenced by factors such as the prevalence of sacroiliitis, ongoing clinical research, and the introduction of new therapies, which collectively create a complex environment for competition. GlaxoSmithKline is a significant player in the France Sacroiliitis Treatment Market, leveraging its robust portfolio of medications to address inflammatory conditions, including sacroiliitis. The company is recognized for its strong research and development capabilities, which enable it to deliver effective treatment options tailored to the specific needs of the French population. GSK maintains a solid market presence supported by strategic collaborations with healthcare professionals, aiding in the dissemination of information regarding their products. Their commitment to patient care and innovative treatment solutions fortifies their position in the market, giving GSK a competitive edge against other players. Amgen possesses a noteworthy footprint in the France Sacroiliitis Treatment Market, focusing on delivering biologic therapies that target immune-mediated disorders. Known for its commitment to innovation, Amgen has introduced key products that have made a significant impact on the management of sacroiliitis, including the development of monoclonal antibody treatments. The company's strong market presence in France is bolstered by strategic partnerships and collaborations with healthcare institutions, facilitating access to its therapies. Amgen continually invests in research to expand its product offerings, enhancing patient outcomes. Additionally, the company has engaged in mergers and acquisitions to bolster its portfolio, allowing it to remain competitive within the French market by providing comprehensive solutions that address the complexities of sacroiliitis treatment. **Key Companies in the France Sacroiliitis Treatment Market Include** - GlaxoSmithKline - Amgen - Bristol-Myers Squibb - Pfizer - Merck - Roche - Gilead Sciences - Johnson & Johnson - Eli Lilly - Celgene - AstraZeneca - AbbVie - Sanofi - Novartis - UCB **France Sacroiliitis Treatment Market Developments** The France Sacroiliitis Treatment Market has witnessed several significant developments recently. In October 2023, Amgen announced positive results from their latest clinical trial involving an innovative treatment for sacroiliitis, which spurred interest within the medical community. Furthermore, in April 2023, Gilead Sciences reported an increase in market valuation due to the introduction of new therapies aimed specifically at managing inflammation associated with sacroiliitis. Key players such as Pfizer and Bristol-Myers Squibb remain focused on expanding their product portfolios in this therapeutic area, particularly with emerging biologics and targeted therapies that can enhance patient outcomes. Recently, AstraZeneca and Eli Lilly have been investing in Research and Development initiatives for drugs that address chronic inflammation and pain management in patients. However, no significant merger or acquisition activity was reported in the sacroiliitis sector involving the mentioned companies within the past few months. Over the past few years, France has seen an increasing prevalence of sacroiliitis, primarily due to lifestyle and environmental factors, highlighting the need for effective treatments and continuing research. This growing patient population may lead to heightened competition among the key market players in France. **Sacroiliitis Treatment Market Segmentation Insights** **Sacroiliitis Treatment Market Type Outlook** - Medications - Joint Injections - Joint Fusion - Radiofrequency Denervation - Electrical Stimulation **Sacroiliitis Treatment Market End-user Outlook** - Hospitals - Clinics - Others ## Market Drivers ### Growing Awareness and Education The increasing awareness and education regarding sacroiliitis and related conditions are pivotal in shaping the sacroiliitis treatment market. Patient education initiatives and awareness campaigns led by healthcare organizations in France have contributed to a better understanding of the symptoms and treatment options available. This heightened awareness encourages individuals experiencing symptoms to seek medical advice sooner, leading to earlier diagnosis and treatment. Moreover, healthcare professionals are receiving enhanced training on the management of sacroiliitis, which may improve patient outcomes. As more patients become informed about their conditions, the demand for effective treatments is likely to rise, thereby stimulating growth in the sacroiliitis treatment market. This trend reflects a broader commitment to improving healthcare delivery and patient engagement. ### Increased Healthcare Expenditure The rise in healthcare expenditure in France is a critical driver for the sacroiliitis treatment market. With the French government investing heavily in healthcare infrastructure and services, there is a growing availability of resources for the diagnosis and treatment of chronic conditions like sacroiliitis. Recent statistics indicate that healthcare spending in France has reached approximately €300 billion, with a significant portion allocated to chronic disease management. This financial commitment facilitates access to advanced treatment options and encourages healthcare providers to adopt innovative therapies. As patients gain better access to care, the demand for effective sacroiliitis treatments is likely to increase, further propelling market growth. The ongoing investment in healthcare is expected to create a favorable environment for the sacroiliitis treatment market. ### Advancements in Treatment Modalities Innovations in treatment modalities are significantly influencing the sacroiliitis treatment market. The introduction of new pharmacological agents, including targeted therapies and biologics, has transformed the management of sacroiliitis. In France, the approval of novel medications has expanded treatment options, allowing for more personalized approaches to patient care. For instance, the use of TNF inhibitors has been shown to reduce inflammation and improve patient outcomes. Additionally, advancements in imaging techniques have enhanced diagnostic accuracy, enabling earlier intervention. This evolution in treatment strategies is likely to attract more patients to seek care, thereby driving market growth. As healthcare providers adopt these new therapies, the sacroiliitis treatment market is poised for expansion, reflecting the ongoing commitment to improving patient outcomes. ### Rising Prevalence of Autoimmune Disorders The increasing incidence of autoimmune disorders in France is a notable driver for the sacroiliitis treatment market. Conditions such as ankylosing spondylitis and psoriatic arthritis, which are often associated with sacroiliitis, have shown a rising trend. Recent data indicates that approximately 0.5-1% of the population in France is affected by ankylosing spondylitis, leading to a growing demand for effective treatment options. This trend is likely to propel the market as healthcare providers seek to address the needs of this patient population. Furthermore, the awareness surrounding these conditions is increasing, prompting more individuals to seek medical attention, thereby expanding the market for sacroiliitis treatments. As the prevalence of these disorders continues to rise, the sacroiliitis treatment market is expected to experience significant growth in the coming years. ### Regulatory Support for Innovative Therapies Regulatory support for innovative therapies is emerging as a significant driver for the sacroiliitis treatment market. In France, the regulatory environment is becoming increasingly favorable for the approval of new treatment options, particularly biologics and targeted therapies. The French National Agency for the Safety of Medicines and Health Products (ANSM) has streamlined processes for evaluating and approving new drugs, which may expedite patient access to cutting-edge therapies. This supportive regulatory framework encourages pharmaceutical companies to invest in research and development, leading to a broader array of treatment options for sacroiliitis. As new therapies gain approval and enter the market, the potential for improved patient outcomes is likely to attract more individuals seeking treatment, thereby driving growth in the sacroiliitis treatment market. ## Future Outlook The [Sacroiliitis Treatment Market](https://www.marketresearchfuture.com/reports/sacroiliitis-treatment-market-6590) is projected to grow at 18.42% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in treatment options. **New opportunities:** - Development of telehealth platforms for remote patient monitoring - Investment in biologics and targeted therapies for enhanced efficacy - Expansion of outpatient treatment facilities to improve accessibility By 2035, the market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Medications (Largest) vs. Joint Injections (Fastest-Growing) In the France sacroiliitis treatment market, the market share is significantly held by Medications, which dominate the segment owing to their widespread use and clinical efficacy in managing pain and inflammation. Joint Injections, while occupying a smaller share, have shown promising demand as they provide targeted relief, which is increasingly appealing to patients seeking alternative treatments. This distribution highlights the current preference trends among healthcare providers and patients alike. Looking forward, the growth trend for Joint Injections is on the rise, projected to expand rapidly as new techniques and formulations are developed. Factors such as an increasing geriatric population and a focus on minimizing opioid use for pain management are driving this segment. Medications will continue to be essential, yet the dynamic nature of patient needs is opening pathways for Joint Injections to emerge robustly in the market. Medications: Dominant vs. Joint Injections: Emerging Medications in the France sacroiliitis treatment market have established themselves as the dominant segment due to their effectiveness and patient familiarity. They include NSAIDs, corticosteroids, and other therapeutic agents, catering to diverse patient needs. Conversely, Joint Injections represent an emerging trend aimed at providing localized pain relief through various substances like corticosteroids and hyaluronic acid. As healthcare providers address specific pain points through targeted treatments, Joint Injections are gaining traction, particularly among patients who prefer less invasive options. This duality presents opportunities for innovation and patient-centric approaches in managing sacroiliitis. ### By End-User: Hospitals (Largest) vs. Clinics (Fastest-Growing) In the France sacroiliitis treatment market, the distribution of market share among end-users reveals that hospitals retain the largest share, leveraging their comprehensive infrastructure and specialized staff. They serve as the primary healthcare providers for patients with sacroiliitis, offering advanced diagnostic and treatment options. In contrast, clinics are emerging rapidly, with an increasing number of patients opting for outpatient services due to their convenience and lower costs, contributing to their growing market presence. Growth trends indicate that while hospitals continue to dominate the market, clinics are witnessing significant expansion driven by rising awareness of sacroiliitis and advancements in treatment options. Factors such as the increasing aging population and the prevalence of sedentary lifestyles are propelling the demand for effective treatment solutions. The trend towards minimally invasive procedures and improved patient experiences in clinics also suggests a robust future growth trajectory for this segment. Hospitals (Dominant) vs. Clinics (Emerging) The hospitals segment stands out as a dominant player in the France sacroiliitis treatment market, characterized by their ability to provide comprehensive care with access to a broad range of medical specialists and advanced technologies. Their well-established networks and infrastructure enable them to manage complex cases effectively, ensuring high-quality patient outcomes. On the other hand, clinics represent an emerging segment that caters to a growing patient base seeking accessible treatment options. With a focus on outpatient care, clinics are positioned to capitalize on trends that favor convenience and efficiency. Their agility in implementing innovative treatment protocols, combined with a personalized approach, allows them to compete effectively while attracting patients who prefer less invasive and quicker treatment alternatives. ## Competitive Benchmarking The sacroiliitis treatment market in France is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as AbbVie Inc (US), Johnson & Johnson (US), and Sanofi S.A. (FR) are actively engaged in enhancing their product offerings and expanding their market presence. AbbVie Inc (US) has positioned itself as a leader in biologics, focusing on the development of advanced therapies that target the underlying mechanisms of sacroiliitis. This strategic emphasis on innovation is indicative of a broader trend within the market, where companies are prioritizing research and development to meet the evolving needs of patients.The market structure appears moderately fragmented, with several players vying for market share. Companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. This tactical approach not only improves operational capabilities but also allows for quicker responses to market demands. The collective influence of these key players is shaping a competitive environment that encourages collaboration and innovation, ultimately benefiting patients through improved treatment options. In October Johnson & Johnson (US) announced a strategic partnership with a leading French biotechnology firm to co-develop a novel treatment for sacroiliitis. This collaboration is expected to leverage cutting-edge research and accelerate the development of new therapies, thereby enhancing Johnson & Johnson's portfolio in the inflammatory disease space. The strategic importance of this partnership lies in its potential to bring innovative solutions to market more rapidly, addressing unmet medical needs in the region. In September AbbVie Inc (US) launched a new clinical trial for its latest biologic therapy aimed at treating sacroiliitis. This trial is significant as it represents AbbVie's commitment to advancing treatment options through rigorous scientific research. The outcomes of this trial could potentially reshape treatment protocols and establish AbbVie as a frontrunner in the therapeutic landscape. In August Sanofi S.A. (FR) expanded its product line by introducing a new oral medication specifically designed for patients with sacroiliitis. This move not only diversifies Sanofi's offerings but also reflects a growing trend towards more accessible treatment options. The introduction of this medication is likely to enhance patient adherence and satisfaction, further solidifying Sanofi's position in the market. As of November the competitive trends within the sacroiliitis treatment market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in drug development. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on technological advancements, innovative therapies, and reliable supply chains. This transition underscores the importance of adaptability and forward-thinking strategies in maintaining a competitive edge. ## Recent News & Developments The France Sacroiliitis Treatment Market has witnessed several significant developments recently. In October 2023, Amgen announced positive results from their latest clinical trial involving an innovative treatment for sacroiliitis, which spurred interest within the medical community. Furthermore, in April 2023, Gilead Sciences reported an increase in market valuation due to the introduction of new therapies aimed specifically at managing inflammation associated with sacroiliitis. Key players such as Pfizer and Bristol-Myers Squibb remain focused on expanding their product portfolios in this therapeutic area, particularly with emerging biologics and targeted therapies that can enhance patient outcomes. Recently, AstraZeneca and Eli Lilly have been investing in Research and Development initiatives for drugs that address chronic inflammation and pain management in patients. However, no significant merger or acquisition activity was reported in the sacroiliitis sector involving the mentioned companies within the past few months. Over the past few years, France has seen an increasing prevalence of sacroiliitis, primarily due to lifestyle and environmental factors, highlighting the need for effective treatments and continuing research. This growing patient population may lead to heightened competition among the key market players in France. ## Report Scope | MARKET SIZE 2024 | 2075.31(USD Million) | | --- | --- | | MARKET SIZE 2025 | 2457.58(USD Million) | | MARKET SIZE 2035 | 13327.54(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 18.42% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | AbbVie Inc (US), Amgen Inc (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Novartis AG (CH), Pfizer Inc (US), Roche Holding AG (CH), Sanofi S.A. (FR) | | Segments Covered | Type, End-User | | Key Market Opportunities | Emergence of biologics and personalized therapies enhances treatment options in the sacroiliitis treatment market. | | Key Market Dynamics | Rising demand for biologics in sacroiliitis treatment reflects evolving patient preferences and regulatory advancements. | | Countries Covered | France | ## Frequently Asked Questions **Q: What was the market valuation for sacroiliitis treatment in France in 2024?** A: The market valuation for sacroiliitis treatment in France was $2075.31 Million in 2024. **Q: What is the projected market valuation for sacroiliitis treatment in France by 2035?** A: The projected market valuation for sacroiliitis treatment in France is $13327.54 Million by 2035. **Q: What is the expected CAGR for the France sacroiliitis treatment market during the forecast period 2025 - 2035?** A: The expected CAGR for the France sacroiliitis treatment market during the forecast period 2025 - 2035 is 18.42%. **Q: Which companies are the key players in the France sacroiliitis treatment market?** A: Key players in the France sacroiliitis treatment market include AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, Johnson & Johnson, Novartis AG, Pfizer Inc, Roche Holding AG, and Sanofi S.A. **Q: What segment had the highest valuation in the France sacroiliitis treatment market in 2024?** A: In 2024, the segment with the highest valuation was medications, amounting to $3800.0 Million. **Q: How much did joint injections contribute to the France sacroiliitis treatment market in 2024?** A: Joint injections contributed $2800.0 Million to the France sacroiliitis treatment market in 2024. **Q: What is the projected growth for electrical stimulation in the France sacroiliitis treatment market by 2035?** A: The projected growth for electrical stimulation in the France sacroiliitis treatment market is expected to reach $3227.54 Million by 2035. **Q: What was the contribution of hospitals as an end-user segment in 2024?** A: In 2024, hospitals contributed $5300.0 Million as an end-user segment in the France sacroiliitis treatment market. **Q: What is the expected valuation for clinics in the France sacroiliitis treatment market by 2035?** A: The expected valuation for clinics in the France sacroiliitis treatment market is projected to be $4000.0 Million by 2035. **Q: How does the performance of the 'others' segment compare to hospitals and clinics in 2024?** A: In 2024, the 'others' segment performed closely with a valuation of $4027.54 Million, compared to hospitals at $5300.0 Million and clinics at $4000.0 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/france-sacroiliitis-treatment-market-53952*